骨巨细胞瘤术后复发的手术治疗

目的:探讨骨巨细胞瘤术后复发的手术方法及疗效。方法:1994年6月-2003年10月,收治四肢长骨复发性骨巨细胞瘤18例,男12例,女6例;年龄18~44岁,平均26岁。股骨下端5例,胫骨上端8例,股骨上端1例,桡骨远端4例。Enneking分期:Ⅰa期14例,Ⅰb期4例。放射影像学Cam-panicci分级:Ⅰ级7例,Ⅱ级7例,Ⅲ级4例。病理学Jaffe分级:Ⅰ级8例,Ⅱ级7例,Ⅲ级3例。采用肿瘤扩大切除,吻合血管的自体腓骨、髂骨联合移植术治疗9例;瘤段切除,吻合血管的腓骨头移植重建术4例;瘤段切除,人工假体置换术5例。结果:随访时间11~110个月,平均66个月。所有移植骨术后均愈合,一侧关节间隙轻度狭窄2例,术后再复发1例。术后功能评价:优13例,良3例,可1例,差1例。结论:肿瘤扩大切除,吻合血管的自体腓骨、髂骨联合移植术既能彻底切除病变,又能保持和重建关节功能,是一种较理想的方法,Campanicci分级Ⅲ级、病理学Jaffe分级Ⅱ~Ⅲ级的复发性骨巨细胞瘤原则上应施行更为广泛的瘤段切除术,桡骨远端复发性骨巨细胞瘤因其部位的特殊性,应用自体腓骨移植重建效果良好。     

胫骨造釉细胞瘤手术方法选择

目的:探讨胫骨造釉细胞瘤手术方法选择的应用价值。方法:胫骨造釉细胞瘤患者5例,男4例,女1例;年龄14⁶1岁,平均37.8岁。5例行手术治疗,先后多次复发。早期行病灶刮除、自体骨、异体骨或人工骨植骨术,全部复发。复发后又先后行瘤段切除、自体游离腓骨移植术,瘤段切除、异体骨移植术。最终4例行截肢术。结果:术后随访10个月³年,平均12.4个月。病灶刮除植骨术后复发5例,3例再行瘤段切除、自体游离腓骨髂骨移植术,其中2例复发;2例再行瘤段切除、异体骨移植术,均复发。复发的4例均采取截肢治疗。出现肺转移1例,行肺转移灶切除术;出现骨转移1例,行髋关节离断术,随访末期死亡0例。结论:虽然胫骨造釉细胞瘤有很高的复发率,但经过积极正确的手术方法治疗,预后尚好。     

带血管蒂腓骨移植修复骨巨细胞瘤段切除后骨缺损

自1986年至今我们采用带血管蒂腓骨就近转位移植,膝关节融合术治疗5例膝部骨巨细胞瘤患者,经随访疗效较为满意。1 临床资料1.1 一般资料 本组5例,女4例,男1例;年龄18～39岁;股骨下端1例,胫骨上端4例;均为骨巨细胞瘤,按Jaffe病理分级,Ⅱ级4例,Ⅲ级1例。均采用带血管蒂腓骨转位移植膝关节融合术,其中胫骨上端巨细胞瘤2例加用股骨下段带腓肠肌蒂骨瓣翻转移位植骨。     

吻合血管腓骨髂骨联合移植修复膝关节周围骨巨细胞瘤切除术后的骨缺损

目的探讨吻合血管的腓骨、髂骨联合移植修复膝关节周围骨巨细胞瘤扩大切除的方法及疗效。方法1996年10月~2002年11月,收治膝关节周围骨巨细胞瘤25例,其中17例采用肿瘤扩大切除,吻合血管的腓骨、髂骨联合移植术,年龄18~44岁。Enneking分期均为A期;放射影像学Campanicci’s分级级11例,级5例,级1例;病理学Jaffe's分级级9例,级7例,级1例。骨缺损范围为5.0cm×4.0cm~8.0cm×5.5cm,采用胫骨近端肿瘤扩大切除吻合血管的腓骨、髂骨联合移植修复肿瘤切除后骨缺损9例,股骨远端肿瘤扩大切除吻合血管的腓骨、髂骨联合移植修复重建肿瘤切除后骨缺损8例。随访观察术后植骨愈合、肿瘤复发情况、膝关节功能以及死亡情况。结果术后17例移植髂骨4.0cm×4.0cm~5.0cm×5.0cm,移植腓骨长度14~20cm,伤口期愈合。均获随访26~87个月,平均54个月。所有移植骨术后均愈合,愈合时间75~120d,平均93d。术后复发2例,关节腔间隙轻度狭窄3例。所有患者膝关节屈伸功能良好,其中股骨远端重建后屈曲80~105°,平均96°;胫骨近端重建后屈曲90~120°,平均110°。根据Enneking下肢功能评价标准,优11例,良3例,可1例,差2例,优良率为82.4%。结论肿瘤扩大切除,应用吻合血管的腓骨、髂骨联合移植修复膝关节周围骨巨细胞瘤具有肿瘤切除相对彻底、复发率低、骨移植愈合时间短、功能恢复快,能尽量保持和重建膝关节结构和功能等优点。     

肢体恶性骨肿瘤及骨转移癌保肢治疗

目的:探讨肢体恶性骨肿瘤及转移癌行瘤段切除假体重建的方法及意义。方法:本组共62例,男38例,女24例;年龄10⁷2岁,平均28.4岁。原发肢体恶性骨肿瘤41例,其中骨肉瘤19例,骨巨细胞瘤9例,恶性纤维组织细胞瘤8例,浆细胞瘤3例,尤文氏瘤1例,骨血管内皮瘤1例。骨转移癌21例,原发病灶分别为:肺癌9例,胃癌3例,肾癌2例,乳腺癌2例,甲状腺癌1例,颌下腺癌1例,原发灶不明者3例。对62例肢体恶性骨肿瘤及转移癌应用肿瘤段切除并修复重建治疗。方法有:①瘤段切除人工假体置换术;②瘤段切除自体腓骨移植术;③瘤段切除髓内针骨水泥重建术。结果:术后随访5⁴2个月,平均14.2个月,41例恶性骨肿瘤中,术后无瘤生存21例,死亡4例,7例发生肺转移,3例发生其他部位转移,6例局部复发后截肢。37例生存患者患肢功能按Enneking骨肿瘤外科治疗后功能评定标准,优良率81.1%。21例骨转移瘤患者中,术后存活3个月以上者19例（占90.4%）;术后疼痛消失15例（占71.4%）,其余均有疼痛减轻;日常生活工作恢复者11例（占52.3%）。结论:对可施行广泛切除的肢体恶性骨肿瘤患者采用不同方法修复重建,行保肢治疗,可在治疗肿瘤的前提下尽量保留肢体功能,对肢体骨转移癌行合适的保肢手术对提高骨转移癌患者的生存质量有积极意义。     

儿童长骨骨巨细胞瘤诊断及外科治疗

[目的]研究儿童四肢长骨骨巨细胞瘤的发病，评价不同手术方式的效果。[方法]对1994年12月～2003年12月本院收治的骨巨细胞瘤患者进行统计分析，根据Enneking分级系统分级，Ⅰ-Ⅱ级采用肿瘤刮除，氯化锌烧灼残腔，双氧水浸泡和异体植骨的方法进行治疗，Ⅲ级采用瘤段切除大段异体骨移植重建，术后定期随访。[结果]在128例骨巨细胞瘤患者中，儿童患者8例发病率为6．3％。其中Ⅰ级2例，Ⅱ级5例，Ⅲ级1例，伴发病理性骨折2例。6例行肿瘤刮除植骨后骨修复完善，肢体无畸形，2例病理性骨折愈合良好；1例异体骨段移植骨愈合良好，无塌陷及骨折，但患肢短缩2．5cm，无移植排斥；1例腓骨上端病变行腓骨小头切除，无功能障碍。术后随访2—9a，平均5．4a，未见肿瘤局部复发和远处肺转移。[结论]骨巨细胞瘤可以发生在儿童四肢长骨，刮除、氯化锌烧灼、双氧水浸泡和异体植骨可以达到满意效果，而瘤段切除会对儿童肢体发育产生影响。     

骨细胞瘤的生物学行为与癌基因蛋白表达的相关性

目的探讨癌基因蛋白表达在骨巨细胞瘤生物学行为与预后方面的意义.方法对46例骨巨细胞瘤(含10例肿瘤复发)进行Jaffe分级与综合分级;同时镜下确认有否侵袭周围组织与出血坏死,结合免疫组织化学技术检测Ki67,bcl-2,c-erbB-2及nm23 4种癌基因蛋白表达.结果在肿瘤的出血坏死、侵袭与复发方面,Ⅰ、Ⅱ、Ⅲ级之间的差异无显著性,Ⅲ级分类与综合分级也无相关性.4种癌基因产物的表达在一定程度上与其侵袭复发有关.结论单纯Ⅲ级分类法在反映骨巨细胞瘤的生物学行为方面存在着一定的局限性.癌基因产物的表达参照综合分级可能成为推断骨巨细胞瘤的性质与预后重要参考指标.     

自体腓骨移植治疗桡骨远端骨巨细胞瘤

目的：探讨白体近端腓骨移植重建在桡骨远端骨巨细胞瘤临床治疗中的应用及效果。方法：对4例桡骨远端骨巨细胞瘤复发（Campanacci Ⅲ级）患者在行桡骨远端瘤段切除的同时,行自体近端腓骨移植重建手术。结果：所有患者随访27～50个月,疼痛症状消失,骨愈合时间5～9个月,平均愈合时间为6．5个月,无移植骨吸收和骨折,腕关节功能握持力为对侧手的55％（40～80％）,背伸活动度可达对侧50％（10～80％）,掌屈达40％（15～70％）,无神经血管损伤症状,恢复正常工作劳动。所有患者均未出现骨巨细胞瘤的复发及肺转移。结论：桡骨远端骨巨细胞瘤经广泛切除后,用自体近端腓骨移植进行保肢治疗,可较好地保留腕关节功能,是一种有效的治疗方法。     

瘤腔内化疗治疗骨巨细胞瘤的长期随访观察

目的 :探讨瘤腔内化疗对骨巨细胞瘤远期疗效的影响。方法 :回顾分析随访时间 5年以上的 13例患者 ,男 6例 ,女 7例。中位年龄为 2 7岁 (2 0～ 61岁 )。胫骨上端 6例 ,股骨下端 3例 ,股骨上端 2例 ,跟骨和尺骨近端各1例。Jaffe分级 :Ⅰ级 2例 ,Ⅱ级 8例 ,Ⅲ级 3例 ;Campanacci分期 :Ⅰ期 4例 ,Ⅱ期 7例 ,Ⅲ期 2例。均采用肿瘤刮除、瘤腔灭活、植骨、瘤腔内化疗的方法治疗。结果 :所有患者均获得 5～ 11年的随访。 2例复发 ,其中 1例因肺转移而死亡。肢体功能评分 3 0分 10例 ,2 6分 1例 ,2 4分 1例。结论 :瘤腔内化疗是一种治疗骨巨细胞瘤可行的方法 ,主要适应于瘤腔完整的骨巨细胞瘤。     

保留肢体的下肢瘤段切除与功能重建

报告本院1983年以来,采用保留肢体的下肢瘤段切除与功能重建4例。例1,为右胫骨上骨端骨巨细胞瘤(Ⅱ级),行瘤段切除、自体带血管腓骨游离移植修复胫骨缺损。随访5年、肢体功能良好,已参加农业劳动,例2,系右股骨下端骨肉瘤,行大腿     

维生素D受体在糖尿病肾病足细胞损伤及蛋白尿缓解中的作用

目的探讨维生素D受体(VDR)在糖尿病肾病(DKD)足细胞中的表达水平及在足细胞损伤及蛋白尿缓解中的作用。方法(1)本研究纳入了65例诊断患有2型糖尿病(伴或不伴蛋白尿)的患者,并纳入了25例年龄和性别相匹配的健康体检者为对照组。根据白蛋白/肌酐(ACR)的尿排泄比例对2型糖尿病患者进行分组,分别为无蛋白尿(ACR<30 mg/g,n=24)、微量白蛋白尿(ACR 30~300 mg/g,n=18)和临床蛋白尿(ACR>300 mg/g,n=23)。另选择25例经肾活检确诊的DKD患者作为DKD组。正常肾脏组织标本均取自泌尿外科同一时期肾脏肿瘤切除患者10例。将各组检测指标进行对比,同时采用实时定量PCR、ELISA法和免疫组化法检测VDR在各组患者的血液、尿液样本和肾脏组织中的表达情况,以及使用Pearson相关分析分析VDR与尿蛋白的相关性。(2)在2型糖尿病肾病小鼠模型中对上述结果进行验证,将遗传背景均为C57BLKs/J的雄性db/db小鼠及同窝出生的db/m小鼠,随机分为正常对照组(A组)、DKD对照组(B组)、DKD二甲基亚砜处理组(C组)、DKD帕立骨化醇(VDR激动剂)处理组(D组),C、D组连续腹腔注射处理8周,对照组不做任何处理。小鼠10周龄时开始连续干预8周,在小鼠22周龄(开始干预后12周)检测各组小鼠体重、血、尿生化指标对比;Western印迹法检测β⁃catenin、VDR的变化;免疫荧光观察足细胞标志蛋白podocin及足细胞损伤蛋白α⁃SMA的表达变化。结果(1)与正常健康对照组相比,无蛋白尿组、微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿组的糖尿病患者相比,微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05)。(2)与正常健康对照组相比,无蛋白尿糖尿病组和DKD组患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿糖尿病组患者相比,DKD组患者血浆中VDR的mRNA和蛋白水平亦较低(均P<0.05)。(3)免疫组化结果显示,DKD组肾组织中VDR的表达明显少于正常对照组。(4)DKD患者血浆中VDR mRNA相对水平与ACR呈负相关(r=-0.342,P<0.05)。(5)各组尿液上清液中VDR的水平与血浆中的水平呈相反趋势。(6)Western印迹结果显示,B组、C组肾小球足细胞β⁃catenin蛋白表达高于D组(均P<0.05),VDR蛋白的表达低于D组(均P<0.05);免疫荧光结果显示,B组、C组肾小球足细胞podocin的表达低于D组(均P<0.05),α⁃SMA的表达高于D组(均P<0.05)。结论VDR高表达缓解DKD足细胞损伤及蛋白尿。     

罗伊适应模式对腹股沟疝无张力疝修补术后恢复情况的影响

目的探讨罗伊适应模式对患者腹股沟疝无张力疝修补术后恢复情况的影响。 方法将2016年1月至2019年5月在秦皇岛市第二医院择期进行无张力修补术治疗的120例腹股沟疝患者，按照随机数字法分为对照组和观察组，每组各60例。对照组采用常规护理治疗，观察组在对照组的基础上采用罗伊适应模式。比较2组患者的术后临床指标、心理状态、围手术期并发症发生情况及满意度。 结果术后观察组患者的首次排气时间、恢复正常饮食时间、离床活动时间和术后住院时间均低于对照组（P<0.05）；术后观察组患者的抑郁自评量表（SDS）和焦虑自评量表（SAS）评分显著低于对照组（P<0.05）；术后2组患者均无切口感染发生，2组患者尿潴留、急性疼痛、认知功能障碍、发热、血肿等发生率相比无统计学差异（P>0.05）；术后观察组患者护理满意度为96.67%，显著高于对照组的83.33%（P<0.05）。 结论在常规护理的基础上，罗伊适应模式用于患者腹股沟疝无张力修补围手术期，能有效改善术后患者的焦虑/抑郁情绪，不增加围手术期并发症，促进术后患者的恢复及提高治疗满意度。     

Long-term follow-up of callotasis lengthening of the capitate after resection of the lunate for the treatment of stage III lunate necrosis

The callotasis lengthening technique was used to gradually lengthen the capitate after resection of the lunate in stage IIIa necrosis in 23 patients. Results of ten patients with a follow-up of at least 5 years showed rapid and sufficient callus formation in every patient regardless of age. The callotasis lengthening modification of the Graner II operation provides all advantages and avoids the major inconvenience of the traditional Graner II operation. There was no increased rate of disturbed fracture healing. Results of the DTPA-gadolinium MRI study did not show any significant impairment of vascularization within the region of the capitate bone. With the “intrinsic bone formation,” contrary to every other intercarpal arthrodesis at the wrist, there is no need for an additional bone graft.     

Comparison of University of Wisconsin and University of Pittsburgh solutions for heart transplantation

The effectiveness of University of Wisconsin (UW) and University of Pittsburgh (UP) solutions for the preservation of rat hearts was compared. Lewis rat hearts were preserved with UW (group A, n=45) or UP (group B, n=45) solution for 0 or 24 h and then transplanted heterotopically into the recipients' abdomen. Ten recipients in each group were observed to obtain 1-week graft survival rates. Tissue water content and tissue content of adenine nucleotides were measured 2 h after transplantation in six grafts from each group. Six hearts preserved for 0 h and seven hearts preserved for 24 h were taken from each group 24 h after grafting for histopathology. The 1-week graft survival rates of groups A24 and B24 were 60% and 10%, respectively. In the 24-h preserved grafts, adenosine triphosphate (ATP) and energy charge [(ATP+adenosine diphosphate/2)/(ATP+adenosine diphosphate+adenosine monophosphate)] of groups A and B were 0.972±0.165 and 0.200±0.123 mg/g wet tissue (P<0.05) and 74.4% and 61.1% (P<0.05), respectively. The tissue water content of group A24 was 71.7%, whereas that of group B24 was 74.1% (P<0.05). Histopathology revealed more severe muscle edema and necrosis and infiltration of polymorphonuclear cells in group B24 than in group A24. We conclude that UW solution is more appropriate for rat heart preservation than UP solution.     

Role of Conventional and Diffusion-Weighted Magnetic Resonance Imaging of Spinal Treatment Protocol for Hydatid Disease

Objective:

To demonstrate the role of magnetic resonance imaging (MRI) in determining the treatment protocol for hydatid disease of the spine.

Design:

Case report; literature review.

Findings:

Diffusion-weighted MRI can help differentiate complicated infected hydatidosis from abscesses, epidermoid cysts from arachnoid cysts, and benign from malignant vertebral compression fractures. It is also helpful in differentiating between abscesses and necrotic tumors.

Conclusion:

Diffusion-weighted MRI can help differentiate between infections requiring immediate surgery and those that can be treated medically with antihelmintic treatment.     

不同尿钙水平的Gitelman综合征患者临床特点比较

目的观察不同尿钙水平Gitelman综合征(GS)患者的临床特点,探讨尿钙在GS疾病临床分型中的价值。方法收集2016—2018年来自中国国家罕见病注册系统(NRSC)、在北京协和医院行SLC12A3基因检测诊断为GS患者的临床资料,分析其尿钙特点,比较不同尿钙水平患者的临床和实验室检查指标。氢氯噻嗪试验按照标准操作流程进行,测定患者基线和用药后3 h内氯离子排泄分数改变量的最大值(ΔFECl)。结果共有83例GS患者被纳入研究,其中低尿钙患者53例(63.86%)。低尿钙组尿钙/肌酐比明显低于非低尿钙组[(0.085±0.058)mmol/mmol比(0.471±0.284)mmol/mmol,t=7.349,P<0.001]。两组患者在年龄、性别、估算肾小球滤过率、血压、血尿电解质水平、代谢性碱中毒方面差异均无统计学意义。低尿钙组患者乏力(χ2=4.595,P=0.032)及多尿(χ2=5.778,P=0.016)发生比例低于非低尿钙组,两组患者在其他临床症状方面差异无统计学意义。低尿钙和非低尿钙组各有16例患者行氢氯噻嗪试验,中位ΔFECl结果分别为0.539%(0.430%,1.283%)和0.829%(0.119%,1.298%),均提示对氢氯噻嗪无反应,组间差异无统计学意义(U=130.000,P=0.956)。结论GS患者中低尿钙比例为63.86%,尿钙水平与疾病临床表型、NCC功能损伤严重程度之间均无明确相关性。     

Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers

BACKGROUND: Sugammadex rapidly reverses rocuronium- and vecuronium-induced neuromuscular block. To investigate the effect of combination of sugammadex and rocuronium or vecuronium on QT interval, it would be preferable to avoid the interference of anaesthesia. Therefore, this pilot study was performed to investigate the safety, tolerability, and plasma pharmacokinetics of single i.v. doses of sugammadex administered simultaneously with rocuronium or vecuronium to anaesthetized and non-anaesthetized healthy volunteers. METHODS: In this phase I study, 12 subjects were anaesthetized with propofol/remifentanil and received sugammadex 16, 20, or 32 mg kg(-1) combined with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1); four subjects were not anaesthetized and received sugammadex 32 mg kg(-1) with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) (n=2 per treatment). Neuromuscular function was assessed by TOF-Watch SX monitoring in anaesthetized subjects and by clinical tests in non-anaesthetized volunteers. Sugammadex, rocuronium, and vecuronium plasma concentrations were measured at several time points. RESULTS: No serious adverse events (AEs) were reported. Fourteen subjects reported 23 AEs after study drug administration. Episodes of mild headache, tiredness, cold feeling (application site), dry mouth, oral discomfort, nausea, increased aspartate aminotransferase and gamma-glutamyltransferase levels, and moderate injection site irritation were considered as possibly related to the study drug. The ECG and vital signs showed no clinically relevant changes. Rocuronium/vecuronium plasma concentrations declined faster than those of sugammadex. CONCLUSIONS: Single-dose administration of sugammadex 16, 20, or 32 mg kg(-1) in combination with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) was well tolerated with no clinical evidence of residual neuromuscular block, confirming that these combinations can safely be administered simultaneously to non-anaesthetized subjects. Rocuronium and vecuronium plasma concentrations decreased faster than those of sugammadex, reducing the theoretical risk of neuromuscular block developing over time.     

Magnetic resonance imaging for the evaluation of rejection of a kindney allograft in the rat

Orthotopic DA (RT1^a) into Lewis (RT1¹) rat kidney allografts and control Lewis-into-Lewis grafts were assessed by magnetic resonance imaging (MRI) and perfusion measurement after intravenous injection of a superparamagnetic contrast agent. MRI anatomical scores (range 1–6) and perfusion rates were compared with graft histology (rank of rejection score 1–6). Not only acute rejection, but also chronic events were monitored after acute rejection was prevented by daily cyclosporine (Sandimmune) treatment during the first 2 weeks after transplantation. In acute allograft rejection (n=11), MRI scores reached the maximum value of 6 and perfusion rates were severely reduced within 5 days after transplantation; histology showed severe acute rejection (histologic score 5–6). In the chronic phase (100–130 days after transplantation), allografts (n=5) manifested rejection (in histology cellular rejection and vessel changes), accompanied by MRI scores of around 2–3 and reduced perfusion rates. Both in the acute and chronic phases, the MRI anatomical score correlated significantly with the histological score (Spearman rank correlation coefficient r _s 0.89, n=30, P<0.01), and perfusion rates correlated significantly with the MRI score or histological score (r _s values between-0.60 and -0.87, n=23, P<0.01). It is concluded that MRI represents an interesting tool for assessing the anatomical and hemodynamical status of a kidney allograft in the acute and chronic phases after transplantation.     

Fibrinogen-thrombin collagen patch reinforcement of highrisk colonic anastomoses in rats

AIM To evaluate the effectiveness of human fibrinogenthrombin collagen patch(TachoSil~?) in the reinforcement of high-risk colon anastomoses.METHODS A quasi-experimental study was conducted in Wistar rats(n = 56) that all underwent high-risk anastomoses(anastomosis with only two sutures) after colectomies. The rats were divided into two randomized groups: Control group(24 rats) and treatment group(24 rats). In the treatment group, high-risk anastomosis was reinforced with TachoSil~? (a piece of Tacho Sil? was applied over this high-risk anastomosis, covering the gap). Leak incidence, overall survival, intra-abdominal adhesions, and histologic healing of anastomoses were analyzed. Survivors were divided into two subgroups and euthanized at 15 and 30 d after intervention in order to analyze the adhesions and histologic changes. RESULTS Overall survival was 71.4% and 57.14% in the TachoSil~? group and control group, respectively(P = 0.29); four rats died from other causes and six rats in the treatment group and 10 in the control group experienced colonic leakage(P 0.05). The intra-abdominal adhesion score was similar in both groups, with no differences between subgroups. We found non-significant differences in the healing process according to the histologic score used in both groups(P = 0.066).CONCLUSION In our study, the use of TachoSil~? was associated with a non-statistically significant reduction in the rate of leakage in high-risk anastomoses. TachoSil~? has been shown to be a safe product because it does not affect the histologic healing process or increase intra-abdominal adhesions.     

Cost-effectiveness of three combinations of antiemetics in the prevention of postoperative nausea and vomiting

Background. This study compares the cost-effectiveness of threecombinations of antiemetics in the prevention of postoperativenausea and vomiting (PONV). Methods. We conducted a prospective, double-blind study. NinetyASA I–II females, 18–65 yr, undergoing general anaesthesiafor major gynaecological surgery, with standardized postoperativeanalgesia (intrathecal 0.2 mg plus i.v. PCA morphine), wererandomly assigned to receive: ondansetron 4 mg plus droperidol1.25 mg after induction and droperidol 1.25 mg 12 h later (Group1); dexamethasone 8 mg plus droperidol 1.25 mg after inductionand droperidol 1.25 mg 12 h later (Group 2); ondansetron 4 mgplus dexamethasone 8 mg after induction and placebo 12 h later(Group 3). A decision analysis tree was used to divide eachgroup into nine mutually exclusive subgroups, depending on theincidence of PONV, need for rescue therapy, side effects andtheir treatment. Direct cost and probabilities were calculatedfor each subgroup, then a cost-effectiveness analysis was conductedfrom the hospital point of view. Results. Groups 1 and 3 were more effective (80 and 70%) thanGroup 2 (40%, P=0.004) in preventing PONV but also more expensive.Compared with Group 2, the incremental cost per extra patientwithout PONV was €6.99 (95% CI, –1.26 to 36.57) forGroup 1 and €13.55 (95% CI, 0.89–132.90) for Group3. Conclusion. Ondansetron+droperidol is cheaper and at least aseffective as ondansetron+ dexamethasone, and it is more effectivethan dexamethasone+droperidol with a reasonable extra cost. Br J Anaesth 2003; 91: 589–92